Greenwich Lifesciences Inc (GLSI) - Total Assets
Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) holds total assets worth $8.88 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Greenwich Lifesciences Inc - Total Assets Trend (2017–2025)
This chart illustrates how Greenwich Lifesciences Inc's total assets have evolved over time, based on quarterly financial data. Also see GLSI market cap overview for the company's overall valuation and market capitalisation.
Greenwich Lifesciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Greenwich Lifesciences Inc's total assets of $8.88 Million consist of 100.0% current assets and 0.0% non-current assets. Review GLSI current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 100.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Greenwich Lifesciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See GLSI live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Greenwich Lifesciences Inc's current assets represent 100.0% of total assets in 2025, an increase from 0.2% in 2017.
- Cash Position: Cash and equivalents constituted 100.0% of total assets in 2025, up from 0.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Greenwich Lifesciences Inc Competitors by Total Assets
Key competitors of Greenwich Lifesciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
|
USA | $667.85 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
Greenwich Lifesciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 1.85 | 63.51 |
| Quick Ratio | 1.54 | 1.85 | 63.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.12 Million | $1.44 Million | $28.45 Million |
Greenwich Lifesciences Inc - Advanced Valuation Insights
This section examines the relationship between Greenwich Lifesciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 70.43 |
| Latest Market Cap to Assets Ratio | 36.71 |
| Asset Growth Rate (YoY) | 50.9% |
| Total Assets | $6.18 Million |
| Market Capitalization | $226.78 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Greenwich Lifesciences Inc's assets at a significant premium (36.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Greenwich Lifesciences Inc's assets grew by 50.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Greenwich Lifesciences Inc (2017–2025)
The table below shows the annual total assets of Greenwich Lifesciences Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.18 Million | +50.91% |
| 2024-12-31 | $4.09 Million | -41.47% |
| 2023-12-31 | $6.99 Million | -48.10% |
| 2022-12-31 | $13.48 Million | -50.48% |
| 2021-12-31 | $27.22 Million | -5.09% |
| 2020-12-31 | $28.68 Million | +107419.79% |
| 2019-12-31 | $26.67K | -75.43% |
| 2018-12-31 | $108.55K | +300.48% |
| 2017-12-31 | $27.10K | -- |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more